IP Library Granted Patent US 7,569,224
Granted Patent B2
US 7,569,224 · App. 11/297,957 · Granted Aug 4, 2009

Mammalian cytokines; receptors; related reagents and methods

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,569,224
App. No.
11/297,957
Granted
Aug 4, 2009
Kind
B2
Abstract

Nucleic acids encoding mammalian cytokine receptor, e.g., for cytokine IL-B50, purified proteins and fragments thereof. Antibodies, both polyclonal and monoclonal, are also provided. Methods of using the compositions for both diagnostic and therapeutic utilities are described.

Claims (9)

1. An isolated or purified antibody or an antigen binding fragment thereof which binds with selectivity to a human IL-B50 receptor complex comprising a human IL7Rα subunit comprising amino acids 21 to 459 of SEQ ID NO:2, and a human Rδ2 subunit comprising amino acids 23 to 371 of SEQ ID NO:4, wherein the antibody does not bind to the polypeptide encoded by SEQ ID NO:2 or to the polypeptide encoded by SEQ ID NO:4.

2. The antibody of claim 1 , wherein the antibody is a monoclonal antibody or an antigen binding fragment thereof.

3. The antibody of claim 1 , wherein the antibody is a humanized monoclonal antibody or an antigen binding fragment thereof.

4. The antibody of claim 1 , wherein the antibody is a human antibody or an antigen binding fragment thereof.

5. The antibody of claim 1 , which inhibits signaling of IL-B50 through the receptor complex.

6. The antibody of claim 5 , wherein the antibody is a monoclonal antibody or an antigen binding fragment thereof.

7. The antibody of claim 5 , wherein the antibody is a humanized monoclonal antibody or an antigen binding fragment thereof.

8. The antibody of claim 5 , wherein the antibody is a human monoclonal antibody or an antigen binding fragment thereof.

9. A pharmaceutical formulation comprising the antibody of claim 1 or an antigen binding fragment thereof and one or more pharmaceutically acceptable carriers.

Assignments (2)
MERGER Recorded Aug 8, 2022
From: MERCK SHARP & DOHME CORP.
To: MERCK SHARP & DOHME LLC
Reel/Frame 061102/0145 →
CHANGE OF NAME Recorded Aug 30, 2012
From: SCHERING CORPORATION
To: MERCK SHARP & DOHME CORP.
Reel/Frame 028884/0151 →